News Sentiment

LENZ sentiment intelligence

LENZ Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 65 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 5.59 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 56

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-5.1% over one week, -17.4% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

We're Hopeful That LENZ Therapeutics (NASDAQ:LENZ) Will Use Its Cash Wisely

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -5.1% Price reacting lower
Trend fit Trend inactive -17.4% over four weeks
Fair value -73.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 39
Negative 10

Relevance

Why the article matched

Direct first
Direct company coverage 56
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
simplywall.st 7
TradingView 6
LENZ Therapeutics 4
Stock Titan 4
Quiver Quantitative 3
www.marketscreener.com 3
GlobeNewswire 3

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 21
Deals and strategy 6
Analyst action 3
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 65
Sahm Direct company coverage

We're Hopeful That LENZ Therapeutics (NASDAQ:LENZ) Will Use Its Cash Wisely

LENZ Therapeutics (NASDAQ:LENZ) had US$258m in cash by March 2026 and burned through US$87m in the last year, giving it a cash runway of about 3.0 years. While its cash burn increased significantly by 68% in the last year, analysts expect the company to reach cashflow breakeven b

Tone
Neutral 50/100
Event
Balance sheet
Published
16 Jul 2026 10:42
Source
Sahm
Market source Direct company coverage

LENZ Therapeutics (LENZ) Stock Fair Value Moves Lower As Analysts Reset Growth Assumptions

Analysts have revised the fair value estimate for LENZ Therapeutics (LENZ) from US$53.71 to US$32.00, reflecting a reset in growth assumptions. While some analysts maintain a bullish stance on long-term prospects, others express caution due to execution risks and valuation concer

Tone
Negative 29/100
Event
Market update
Published
11 Jul 2026 08:09
Source
Market source
VisionMonday.com Direct company coverage

LENZ Therapeutics Launches VIZZ Telehealth Prescribing Option for the Treatment of Presbyopia

LENZ Therapeutics has launched a new telehealth platform for VIZZ (aceclidine ophthalmic solution) 1.44%, an eye drop for presbyopia. This platform offers convenient online evaluations by independent licensed eyecare providers, e-pharmacy prescription fulfillment, and home delive

Tone
Positive 71/100
Event
Market update
Published
08 Jul 2026 12:18
Source
VisionMonday.com
LENZ Therapeutics Direct company coverage

LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ

LENZ Therapeutics has launched a new telehealth prescribing option for VIZZ (aceclidine ophthalmic solution) 1.44%, an eye drop for presbyopia. This platform allows patients to receive online evaluations from licensed eye care providers, prescription fulfillment, and home deliver

Tone
Positive 72/100
Event
Market update
Published
07 Jul 2026 05:11
Source
LENZ Therapeutics
Market source Direct company coverage

LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia

LENZ Therapeutics has launched a new telehealth prescribing option for VIZZ® (aceclidine ophthalmic solution) 1.44%, an eye drop for presbyopia. This platform, accessible via VIZZ.com, allows patients to consult with independent licensed eye care providers online, receive prescri

Tone
Positive 71/100
Event
Market update
Published
06 Jul 2026 18:10
Source
Market source
Stock Titan Direct company coverage

LENZ lets eligible patients get VIZZ online, with home delivery

LENZ Therapeutics has launched a new telehealth prescribing option for its VIZZ aceclidine ophthalmic solution, designed to treat presbyopia. This platform, accessible via VIZZ.com, connects patients with licensed eye care providers for online evaluations, e-pharmacy prescription

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 12:41
Source
Stock Titan
Quiver Quantitative Direct company coverage

LENZ Therapeutics Launches Telehealth Access for VIZZ Alongside National TV Campaign

LENZ Therapeutics has launched telehealth accessibility for its presbyopia treatment, VIZZ (aceclidine ophthalmic solution) 1.44%, allowing patients to receive online evaluations, e-pharmacy prescription fulfillment, and home delivery. This initiative coincides with a national ad

Tone
Positive 65/100
Event
Market update
Published
06 Jul 2026 12:20
Source
Quiver Quantitative
Finviz Direct company coverage

LENZ - LENZ Therapeutics Inc Options

This article provides comprehensive financial data for LENZ Therapeutics Inc. (LENZ), including its last closing price, market capitalization, income, sales, and various financial ratios. It also details insider and institutional ownership, stock performance metrics, and analyst

Tone
Negative 38/100
Event
Analyst action
Published
03 Jul 2026 04:40
Source
Finviz
Stock Titan Direct company coverage

Director departure and audit committee change at LENZ Therapeutics (NASDAQ: LENZ)

LENZ Therapeutics announced changes to its Board of Directors and Audit Committee following the resignation of director Zach Scheiner on June 30, 2026. Scheiner's departure was not due to any dispute, and the Board subsequently reduced its size to six members. Additionally, Jeff

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 21:10
Source
Stock Titan
TradingView Direct company coverage

Price to sales forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ

This article focuses on the "Price to sales forward" metric for LENZ Therapeutics, Inc. (NASDAQ: LENZ). It appears to be a financial data snippet from TradingView, providing an overview of the company's stock performance. The content includes general market information and links

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 15:39
Source
TradingView
TradingView Direct company coverage

Price to book forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ

This article provides a brief financial update on LENZ Therapeutics, Inc. (NASDAQ: LENZ), specifically focusing on its price-to-book forward ratio. The content indicates the market is currently closed, with no trades, and offers information on the company's financials, news, and

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 02:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ

This article provides financial information for LENZ Therapeutics, Inc. (NASDAQ: LENZ), specifically focusing on its enterprise value to revenue forward. The content appears to be a financial snapshot from TradingView, detailing various data points and market information relevant

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 04:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ

This article provides the "Price to earnings forward" metric for LENZ Therapeutics, Inc. (NASDAQ: LENZ). It's presented within the context of TradingView's financial data offerings for the company. The page focuses on a specific financial data point rather than a detailed analyti

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 02:09
Source
TradingView
marketscreener.com Direct company coverage

LENZ Therapeutics, Inc.(NasdaqGS:LENZ) added to Russell Microcap Value Benchmark Index

LENZ Therapeutics, Inc. (NasdaqGS:LENZ), a biopharmaceutical company focused on developing treatments for presbyopia, has been added to the Russell Microcap Value Benchmark Index. This news follows a period of significant activity for the company, including recent license agreeme

Tone
Positive 67/100
Event
Market update
Published
29 Jun 2026 16:38
Source
marketscreener.com
www.marketscreener.com Direct company coverage

LENZ Therapeutics, Inc.(NasdaqGS: LENZ) added to Russell 2000 Value Benchmark

LENZ Therapeutics, Inc. (NasdaqGS: LENZ) has been added to the Russell 2000 Value Benchmark Index. This news follows several recent updates for the biopharmaceutical company, including its addition to the Russell Microcap Value Benchmark and an exclusive licensing agreement for i

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 16:09
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

LENZ Therapeutics, Inc.(NasdaqGS:LENZ) dropped from Russell Small Cap Comp Growth Benchmark

LENZ Therapeutics, Inc. (NasdaqGS:LENZ) has been removed from the Russell Small Cap Comp Growth Benchmark. This news follows a previous report that the company was also dropped from the Russell 3000 Growth Benchmark. The company, which is a pre-commercial stage biopharmaceutical

Tone
Negative 29/100
Event
Market update
Published
29 Jun 2026 09:44
Source
www.marketscreener.com
Stock Titan Direct company coverage

Millennium Group reports 1.60M-share (5.1%) LENZ stake (LENZ)

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have reported a shared voting and dispositive power over 1,603,512 shares, or 5.1%, of LENZ Therapeutics, Inc. Common Stock. This disclosure was made via a Schedule 13G filing, indicating a passiv

Tone
Neutral 50/100
Event
Deals and strategy
Published
26 Jun 2026 20:39
Source
Stock Titan
TradingView Direct company coverage

LENZ Therapeutics, Inc. Actuals & Estimates (NASDAQ:LENZ)

This article provides an overview of LENZ Therapeutics, Inc. (NASDAQ: LENZ) stock performance, financial data, and analyst estimates. It includes current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings report details. The company's

Tone
Negative 35/100
Event
Earnings
Published
26 Jun 2026 05:39
Source
TradingView
Sahm Direct company coverage

LENZ Therapeutics Eye Drug Profile Supports Blockbuster Opportunity: Analyst

LENZ Therapeutics has signed an exclusive licensing and commercialization agreement with Arrotex Pharmaceuticals for its FDA-approved eye drop therapy, VIZZ, targeting presbyopia in Australia and New Zealand. This marks LENZ's fifth such international partnership, with an analyst

Tone
Positive 81/100
Event
Analyst action
Published
26 Jun 2026 01:10
Source
Sahm
www.marketscreener.com Direct company coverage

LENZ Therapeutics, Inc. and Arrotex Pharmaceuticals Pty Ltd. Announce Exclusive License and Commercialization Agreement for VIZZ in Australia and New Zealand

LENZ Therapeutics, Inc. has announced an exclusive license and commercialization agreement with Arrotex Pharmaceuticals Pty Ltd. for its presbyopia treatment, VIZZ, in Australia and New Zealand. LENZ Therapeutics will receive an upfront payment and a significant share of gross pr

Tone
Positive 71/100
Event
Market update
Published
25 Jun 2026 12:11
Source
www.marketscreener.com
Investing.com South Africa Direct company coverage

LENZ licenses presbyopia drug VIZZ to Arrotex for Australia, NZ By Investing.com

LENZ Therapeutics has granted Arrotex Pharmaceuticals exclusive rights to register and commercialize its presbyopia drug VIZZ in Australia and New Zealand. LENZ will receive an upfront payment and profit share from sales of VIZZ, a once-daily eye drop that received FDA approval i

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 02:41
Source
Investing.com South Africa
LENZ Therapeutics Direct company coverage

LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand

LENZ Therapeutics and Arrotex Pharmaceuticals have entered into an exclusive license and commercialization agreement for VIZZ™ eye drops in Australia and New Zealand. This partnership will see Arrotex, Australia’s largest pharmaceutical company, register and commercialize VIZZ, L

Tone
Positive 72/100
Event
Deals and strategy
Published
25 Jun 2026 01:40
Source
LENZ Therapeutics
grafa.com Direct company coverage

LENZ Therapeutics signs exclusive VIZZ deal for Australia and New Zealand

LENZ Therapeutics (NASDAQ:LENZ) has finalized an exclusive licensing and commercialization agreement with Arrotex Pharmaceuticals for its presbyopia treatment, VIZZ, in Australia and New Zealand. This partnership provides LENZ with an upfront payment and a significant share of gr

Tone
Positive 74/100
Event
Deals and strategy
Published
24 Jun 2026 16:40
Source
grafa.com
Investing.com Direct company coverage

LENZ licenses presbyopia drug VIZZ to Arrotex for Australia, NZ

LENZ Therapeutics, Inc. has entered into an exclusive license and commercialization agreement with Arrotex Pharmaceuticals Pty Ltd. for its presbyopia drug, VIZZ, in Australia and New Zealand. LENZ will receive an upfront payment and a profit share from sales of VIZZ, a once-dail

Tone
Neutral 50/100
Event
Earnings
Published
24 Jun 2026 13:40
Source
Investing.com
GlobeNewswire Direct company coverage

LENZ Therapeutics and Arrotex Pharmaceuticals Announce

LENZ Therapeutics and Arrotex Pharmaceuticals have entered into an exclusive license and commercialization agreement for VIZZ™ in Australia and New Zealand. This agreement will allow Arrotex to register and commercialize VIZZ, LENZ's FDA-approved aceclidine-based eye drop for pre

Tone
Positive 74/100
Event
Market update
Published
24 Jun 2026 12:40
Source
GlobeNewswire
Stock Titan Direct company coverage

LENZ expands VIZZ beyond the U.S. with Australia, NZ deal

LENZ Therapeutics has partnered with Arrotex Pharmaceuticals for the exclusive license and commercialization of VIZZ, their FDA-approved presbyopia eye drop, in Australia and New Zealand. This agreement is LENZ's fifth ex-U.S. commercialization deal for VIZZ and includes an upfro

Tone
Positive 75/100
Event
Deals and strategy
Published
24 Jun 2026 12:39
Source
Stock Titan
Simply Wall Street Direct company coverage

LENZ Therapeutics (NasdaqGS:LENZ) Stock Forecast & Analyst Predictions

LENZ Therapeutics (NasdaqGS:LENZ) is forecast to grow earnings and revenue significantly, but is expected to remain unprofitable for the next three years, with projected negative return on equity. Recent analyst revisions show decreased revenue forecasts and increased loss projec

Tone
Negative 33/100
Event
Earnings
Published
24 Jun 2026 12:39
Source
Simply Wall Street